Live attenuated vaccines: Historical successes and current challenges

Virology

Volumn 479-480, Issue , 2015, Pages 379-392

  Minor, Philip D ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Live viral vaccines; Measles; Mumps; Polio; Rotavirus; Smallpox; Vectored vaccines; Yellow fever

Indexed keywords

LIVE VACCINE; VIRUS VACCINE;

CLINICAL TRIAL (TOPIC); HISTORY; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; VIRUS DISEASES;

CLINICAL TRIALS AS TOPIC; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS DISEASES;

EID: 84937141824     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.03.032     Document Type: Review

References (145)

1. Aaby P., Knudsen K., Whittle H., Lisse I.M., Thaarup J., Poulsen A., Sodemann M., Jakobsen M., Brin L., Anstead U., Permin A., Jensen T.G., Andersen H., da Silva M.C. J. Pediatr. 1993, 122:904-908.
2. Afzal M.A., Pickford A.R., Forsey T., Heath A.B., Minor P.D. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J. Gen. Virol. 1993, 74:917-920.
3. Afzal M.A., Minor P.D. Immune response and vaccine efficacy. Vaccine 1999, 17:1813.
4. Afzal M.A., Marsden S.A., Hull R.M., Pipkin P.A., Bentley M.L., Minor P.D. Evaluation of the neurovirulence test for mumps vaccines. Biologicals 1999, 27:43-49.
5. Afzal M.A., Minor P.D. Vaccines, Crohn's disease and autism. Mol. Psychiatry 2002, 7(Suppl. 2):S49-S50.
6. Afzal M.A., Dussupt V., Minor P.D., Pipkin P.A., Fleck R., Hockley D.J., Stacey G.N. Assessment of mumps virus growth on various continuous cell lines by virological immunological, molecular and morphological investigations. J. Virol. Methods 2005, 126:149-156.
7. Afzal M.A., Ozoemena L.C., O'Hare A., Kidger K.A., Bentley M.L., Minor P.D. Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK. J. Med. Virol. 2006, 78:623-630.
8. Bakker W.J., Mathias R.G. Mumps caused by an inadequately attenuated measles, mumps and rubella vaccine. Can. J. Infect. Dis. 2001, 12:144-148.
9. Balraj V., Miller E. Complications of mumps vaccines. Rev. Med. Virol. 1995, 5:219-227.
10. Bankamp B., Takeda M., Zhang Y., Wu W., Rota P.A. Genetic characterization of measles vaccine strains. J. Infect. Dis. 2011, 204(Suppl. 1):S533-S548.
11. Barrett A.D., Monath T.P., Cropp C.B., Adkins J.A., Ledger T.N., Gould E.A., Schlesinger J.J., Kinney R.M., Trent D.W. Attenuation of wild type yellow fever virus by passage in HeLa cells. J. Gen. Virol. 1990, 71:2301-2306.
12. Barrett A.D., Teuwen D.E. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr. Opin. Immunol. 2009, 21:308-313.
13. Baxby D. Small Pox Vaccine, Ahead of its Time 2001, The Jenner Museum, Berkley, UK.
14. Baxby D. Classic paper: studies in smallpox and vaccination. Rev. Med Virol. 2002, 12:201-210. (Smallpox duration of immunity).
15. Beck M., Welsz-Malecek R., Mesko-Prejac M., Radman V., Juzbasic M., Rajninger-Miholic M., Prislin-Musklic M., Dobrovsak-Sourek V., Smerdel S., Stainer D.W. Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. J. Biol. Stand. 1989, 17:85-90.
16. Beijerinck, M.W., 1898 [1968]. Concerning a contagium vivum fluidum as cause of the spot disease of tobacco leaves. In: Johnson, J. (translator/editor), Phytopathological Classics, Number 7. American Phytopathological Society, St. Paul, MN, pp. 33-52.
17. Bodian D. Emerging concept of poliomyelitis infection. Science 1955, 122:105-108.
18. Boni J., Stalder J., Reigel F., Schupbach J. Detection of reverse transcriptase in live attenuated virus vaccines. Clin. Diag. Virol. 1996, 5:43-53.
19. Boulger L.R., Marsden S.A., Magrath D.I., Taffs L.F., Schild G.C. Comparative neurovirulence of Sabin type 3 polio virus vaccines. J. Biol. Stand. 1979, 7:97-111.
20. Boxall N., Kubinyiova M., Prikazsky V., Benes C., Castkova J. An increase in the number of mumps cases in the Czech Republic, 2005, 2006. EuroSurveillance 2008, 13(6). pii:18842.
21. Brown E.G., Wright K.E. Genetic studies on a mumps vaccine strain associated with meningitis. Rev. Med. Virol. 1998, 8:129-142.
22. Buynak E.B., Peck H.M., Creamer A.A., Goldner H., Hilleman M.R. Am. J. Dis. Child. 1962, 103:460-473.
23. Buynak E.B., Hilleman M.R. Live attenuated mumps virus vaccine 1. Vaccine development. Proc. Soc. Exp. Biol. Med. 1966, 123:768-775.
24. Cammack N., Phillips A., Dunn G., Patel V., Minor P.D. Intertypic genomic rearrangement of poliovirus vaccine strains in vaccinnees. Virology 1988, 157:507-514.
25. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I.H.J.M., Chotpitayasunondh T., Chua M.N., Luong C.Q., Rusmil K., Wirawan D.N., Nallusamy R., Pitisuttithum P., Thisakorn U., Yoon I.-K., der Vliet D., Langevin E., Laot T., Hutagalung Y., Frago C., Boaz M., Wartel T.A., Tornieporth N.G., Saville M., Bouckenooghe A., the CYD14 study Group Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked placebo-controlled trial. Lancet 2014, 384:1358-1365.
26. Cheek J.E., Baron R., Atlas H., Wilson D.L., Crider R.D. Mumps outbreak in a highly vaccinated school population. J. Am. Med. Assoc. 1995, 263:2467-2471.
27. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., Orenstein W.A. Measles antibody: reevaluation of protective titres. J. Infect. Dis. 1990, 162:1036-1042.
28. Christenson B., Bottiger M. Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus. Biologicals 1990, 18:213-219.
29. Chumakov K.M., Powers L.B., Newman K.E., Robinson I.B., Levenbook I.S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for the acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. USA 1991, 88:199-203.
30. Chumakov K.M., Norwood L.P., Parker M.L., Dragunsky E.M., Levenbook I.S. RNA sequence variants and their relation to neurovirulence. J. Virol. 1992, 66:966-970.
31. Cockburn W.C. The work of the WHO consultative group on poliomyelitis vaccines. Bull. World Health Organ. 1988, 66:143-154.
32. da Cunha S.S., Rodrigues L.C., Barreto M.L., Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad Zagreb mumps strain. Vaccine 2002, 20:1106-1112.
33. De Mol P., Zissis G., Butzler I.P., Mutwewingabo A., Andre F.E. Failure of live attenuated rotavirus vaccine. Lancet 1986, ii, 108.
34. Deshpande J.M., Nadkarni S.S., Siddiqui Z.A. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J. Med. Res. 2003, 11:217-223.
35. Duclos P., Ward B.J. Measles vaccines: a review of adverse events. Drug Saf. 1998, 19:435-454.
36. Dunn G., Begg N.T., Cammack N., Minor P.D. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J. Med. Virol. 1990, 32:92-95.
37. Dupuy A.P., Despres P., Cahour A., Girard M., Bouloy M. Nucleotide sequence comparison of the genomes of two 17D-204 yellow fever vaccines. Nucl. Acids Res. 1989, 17:3989-3995.
38. Enders J.F., Peebles T.C. Propagation in tissue culture of cytopayhognic agents from patients with measles. Proc. Soc. Exp. Biol. Med. 1954, 86:277-286.
39. Engel A.R., Vasconcelos P.F., McArthur M.A., Barrett A.D. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006, 25:2941-2950.
40. Ferguson M., Heath A.B. Collaborative study to assess the suitability of a candidate. Int. Stand. Yellow Fever Vaccine Biol. 2004, 32:195-205.
41. Fox J.P., Lenette E.H., Manso C., Souza Aguiar J.R. Encephalitis in man following vaccination with 17D yellow fever virus. Am. J. Hyg. 1942, 36:117-142.
42. Fox J.P., Penna H.A. Behavior of 17D yellow fever virus in rhesus monkeys. Relation to substrain dose, and neural or extraneural inoculation. Am. J. Hyg. 1943, 38:152-172.
43. Frierson J.G. The yellow fever vaccine: a history. Yale J. Biol. Med. 2010, 83:77-85. (last accessed 03.12.14). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892770/.
44. Fu C., Tate J.E., Jiang B. Effectiveness of Lanzhou lamb rotavirus vaccine against hospitalized gastroenteritis: further analysis and update. Hum. Vaccines 2010, 6:953.
45. Fulginiti V.A., Eller J.J., Downie A.W., Kempe C.H. Altered reactivity to measles virus: atypical measles in children previous immunized with inactivated measles virus vaccines. J. Am. Med. Assoc. 1967, 202:1075-1080.
46. Fulginiti V.A., Heller R.A. Atypical measles in adolescent siblings 16 years after killed measles vaccine. J. Am. Med. Assoc. 1980, 244:804-806.
47. Galler R., Post P.R., Santos C.N., Ferreira I.I. Genetic variability among yellow fever virus 17D substrains. Vaccine 1998, 16:1024-1028.
48. Gilliland S.M., Jenkins A., Parjer L., Somdach S., Pattamadilok S., Incomserb P., Berry N., Schepelman S., Minor P. Vaccine-related mumps infections in Thailand and the identification of a novel mutation in the mumps fusion protein. Biologicals 2013, 41:84-87.
49. Glass R.I., Bresee J.S., Turcios R., Fischer T.K., Parashar U.D., Steele A.D. Rotavirus vaccines: targeting the developing world. J. Infect. Dis. 2005, 192:S160-S166.
50. Gluck R., Hoskins J.M., Wegmann A., Just M., Germanier R. Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells. Dev. Biol. Stand. 1986, 65:29-35.
51. Goh K.T. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet 1999, 354:1355-1356.
52. Hahn C.S., Dalrymple J.M., Strauss J.H., Rice C.M. Comparison of the virulent asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl. Acad. Sci. USA 1987, 84:2019-2023.
53. Hearn H.J., Soper W.T., Miller W.S. Loss in virulence of yellow fever virus serially passaged in HeLa cells. Proc. Soc. Exp. Biol. Med. 1965, 119:319-322.
54. Hilleman M.R., Buynak E.B., Weibel R.E., Stokes J., Whitman J.E., Leagus M.B. Development and evaluation of the Moraten measles virus vaccine. J. Am. Med. Assoc. 1968, 206:587-590.
55. Hirayama M. Measles vaccines used in Japan. Rev. Infect. Dis. 1983, 5:495-503.
56. Ikic, D., Beck, M., Iuzbasic, M., 1970. Characterization of Edmonston-Zagreb measles virus. In: Proceedings of the Symposium on Human Diolois Cells. Yugosalv Academy of Sciences and Arts, Zagreb, pp. 121-129.
57. Ikic D., Iuzbasic M., Beck M., Hrabar A., Cimbur-Schreiber T. Attenuation and characterization of Edmonston-Zagreb measles virus. Ann. Immunol. Hung. 1972, 16:175-181.
58. Jenner Bartleby Jenner E (1749-1823): the three original publications on vaccination against smallpox. Harv. Class. 1798, 1909-1914. (last accessed 27.11.14). http://www.bartleby.com.
59. Jennings A.D., Gibson C.A., Miller B.R., Mathews J.H., Mitchell C.J., Roehrig J.T., Wood D.J., Taffs F., Sil B.K., Whitby S.N., Whitby J.E., Monath T.P., Minor P.D., Sanders G., Barrett A.D.T. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 1994, 169:512-518.
60. Jin L., Rima B., Brown D., Orvell C., Tecle T., Afzal M., Uchida K., Nakayama T., Song J.W., Kang C., Rota P.A., Xu W., Featherstone D. Proposal for genetic characterisation of wildtype mumps strains: preliminary standardisation of the nomenclature. Arch. Virol. 2005, 150:1903-1909.
61. Johnson C.D., Goodpasture E.W. An investigation of the etiology of mumps. J. Exp. Med. 1934, 59:1-19.
62. Kaic B., Gjenero-Margan I., Aleraj B., Ljubin-Sternak S., Vilibic-Cavlec T., Kilvain S., Pavic D., Stojanovic D., Ilic A. Transmission of the L-Zagreb mumps vaccine virus Croatia, 2005-2008. EuroSurveillance 2008, 13(16). pii 18843.
63. Kew O., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garisch Z., Andre J., Blackman E., Freeman C.J., Jorba J., Sutter R., Tambini G., Venczei L., Pedreira C., Laender F., Shimizu H., Yoneyama T., Miyahura T., van der Avoort H., Oberste M.S., Kilpatrick D., Cochi S., Pallansch M., de Quadros C. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002, 296:356-359. 10.1126/science.1068284pmid:11896235.
64. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., Parrot R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 1968, 89:422-434.
65. Kobune F., Sakata H., Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J. Virol. 1990, 64:700-705.
66. Kobune F., Takahashi H., Terao K., Ohkawa T., Ami Y., Suzaki Y., Nagata N., Sakata H., Yamanouchi K., Kai C. Non human primate models of measles. Lab. Anim. Sci. 1996, 46:315-320.
67. Landsteiner K., Popper E. Ur bertragung der Poliomyelitis acuta auf Affen. Z. Immunitaetsforsch. Exp. Ther. 1909, 2:377-390. (in German).
68. Lazarus A.S., Eddie A., Meyer K.F. Propagation of variola virus in the developing egg. Proc. Soc. Exp. Med. 1937, 36:7-8.
69. Macadam A.J., Pollard S.R., Ferguson G., Dunn G., Skuce R., Almond J.W., Minor P.D. The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 1991, 181:451-458.
70. Macadam A.J., Pollard S.R., Ferguson G., Skuce R., Wood D., Almond J.W., Minor P.D. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 1993, 192:18-26.
71. Macadam A.J., Ferguson G., Stone D.M., Meredith J., Knowlson S., Auda G., Almond J.W., Minor P.D. Rational design of genetically stable, live attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 2006, 80:8653-8663.
72. MacCallum F.O. Hypogammaglobulinaemai in the United Kingdom, VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemai. Spec. Rep. Ser. Med. Res. Counc. 1971, 310:72-85.
73. MacLennan C., Dunn G., Huissoon A.P., Kumararatne D.S., Martin J., O'Leary P., Thompson R.A., Husam Osman H., Wood P., Minor P., Wood D.J., Pillay P. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004, 363:1509-1513.
74. McVail J.C. Smallpox in Glasgow 1900-1902. Br. Med. J. 1902, 40-43. (reprinted (2012) in Rev. Med. Virol. 12; 267-278).
75. Makino S. Development and characteristics of live AIK-C measles virus vaccine: a brief report. Rev. Infect. Dis. 1983, 5:504-505.
76. Marsden S.A., Boulger L.R., Magrath D.I., Reeve P., Schild G.C., Taffs L.F. Monkey neurovirulence of live, attenuated (Sabin) type I and type II poliovirus vaccines. J. Biol. Stand. 1980, 8:303-309.
77. Miller E., Hill A., Morgan-Capner P., Forsey T., Rush M. Antibodies to measle mumps and rubella in UK children 4 years aftervaccination with different MMR vaccines. Vaccine 1995, 13:799-809.
78. Minor P.D. Comparative biochemical studies of type 3 poliovirus. J. Virol. 1980, 34:73-84.
79. Minor P.D. The molecular biology of poliovaccines. J. Gen. Virol. 1992, 73:3065-3077.
80. Minor P.D. Poliovirus. Viral Pathogenesis 1997, 555-574. Lipincott Raven, Philadelphia, New York. N. Nathanson, R. Ahmed, F. Ganzalez-Scarano, D.E. Griffin, K.V. Holmes, F.A. Murphy, H.L. Robinson (Eds.).
81. Minor P.D. Neurovirulence tests of three 17D yellow fever vaccine strains. Biologicals 2011, 39:167-170.
82. Minor P.D. Considerations for setting the specifications of vaccines. Expert Rev. Vaccines 2012, 11:579-585.
83. Minor P.D. The polio eradication programme and issues of the endgame. J. Gen. Virol. 2012, 93:457-474.
84. Minor P.D., John A., Ferguson M., Icenogle J.P. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccine. J. Gen. Virol. 1986, 67:693-706.
85. Minor P.D., Dunn G., Evans D.M.A., Magrath D.I., John A., Howlett J., Phillips A., Westrop G., Wareham K., Almond J.W., Hogle J.M. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J. Gen. Virol. 1989, 70:1117-1123.
86. TM: recombinant live attenuated vaccines against flavivirus infections. Vaccine 2002, 20:1004-1018.
87. Moss W.J., Ota M.O., Griffin D.E. Measles: immune suppression and immune responses. Int. J. Biochem. Cell Biol. 2004, 36:1380-1385.
88. Mrazova M., Smelhausova M., Sestakova Z., Svandova E., Benes C. The 2001 serological surey in the Czech Republic-mumps. Cent. Eur. Piblic Health 2003, 11(Suppl.):S50-S53.
89. Nakano J.H., Gelfond H.M., Cole J.T. Antigenic segregation of type 3 poliovirus isolates realted and unrelated to Sabin's vaccine strain with the use of modified Wecker and McBride techniques. Am. J. Epidemiol. 1966, 83:130-145.
90. Nathanson N. The pathogenesis of poliomyelitis: what we don't know. Adv. Virus Res. 2008, 71:1-50.
91. Nkowane B.U., Wassilak S.G., Orenstein W.A. Vaccine associated paralytic poliomyelitis in the United States:1973 through 1984. J. Am. Med. Assoc. 1987, 257:1335-1340.
92. Norrby E., Enders-Ruckle G., Ter Meulen V. Difference in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J. Infect. Dis. 1975, 132:262-269.
93. Nottay B.K., Kew O.M., Hatch M.H., Heyward J.T., Obijeski J.F. Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans. Virology 1981, 108:405-423.
94. Omata T., Kohara M., Kuge S., Komatsu T., Abe S., Semler B.L., Kameda A., Itoh H., Arita M., Wimmer E., Nomoto A. Genetic analysis of the attenuation phenotype of poliovirus type 1. J. Virol. 1986, 58:348-358.
95. Parker L., Gilliland S.M., Minor P., Schepelman S. Assessment of the ferret as an in vivo model for mumps virus infection. J. Gen. Virol. 2013, 94:1200-1205.
96. Paul J.R. A History of Poliomyelitis 1971, Yale University Press, New Haven, CT.
97. Pastoret P.P., Brochier B., Boulanger D. Target and non-target effects of a recombinant vaccinia-rabies virus developed for fox vaccination against rabies. Dev. Biol. Stand. 1995, 84:183-194.
98. Pfister M., Kursteiner O., Hilfker H., Favre D., Durrer P., Ennaji A., L'Age-Stehr J.L., Kaufhold A., Herzog C. Immunogencity and safety of Berna YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am. J. Trop. Med. Hyg. 2005, 72:339-346.
99. Pipkin P.A., Afzal M.A., Heath A.B., Minor P.D. Assay of humoral immunity to mumps virus. J. Virol. Methods 1999, 79:219-225.
100. Plotkin S.A., Cadoz M., Meignier B., Meric C., Leroy O., Exler J.-L., Tartaglia J., Paoletti E., Gonczol E., Chappuis G. The safety and use of canarypox vectored vaccines. Dev. Biol. Stand. 1995, 84:165-170.
101. Polack F.P., Auwaaerter P.G., Lee S.-H., Nousari H.C., Valsamakis A., Leiferman K.M., Diwan A., Adams R.J., Griffin D.E. Production of atypical measles in rhesus macaque: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 1999, 5:629-633.
102. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., Santiago S., Marmot M., Lally M., Novak R.M., Brown S.J., Kulkarni P., Dubey S.A., Kierstead L.S., Casimiro D.R., Mogg R., DiNubile M.J., Shiver J.W., Leavitt R.Y., Robertson M.N., Mehrotra D.V., Quirk E., Merck V520-016 Study Group Safety and aimmunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 2008, 46:1769-1781.
103. Rice C.M., Lenches E., Eddy S.R., Shin S.J., Sheets R.L., Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985, 229:726-733.
104. Robertson J.S., Minor P.D. Reverse transcriptase activity in vaccines derived from chick cell. Biologicals 1996, 24:289-290.
105. Rubin S.A., Afzal M.A., Powell C.L., Bentley M.L., Auda G.R., Taffs R.E., Carbone K.M. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J. Infect. Dis. 2005, 191:1123-1128.
106. Sabin A.B., Henessen W.A., Winsser J. Studies of variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunological types. J. Exp. Med. 1954, 99:551-576.
107. Sabin A.B., Ward R. The natural history of human poliomyelitis. I. Distribution of virus in nervous and non-nervous tissues. J. Exp. Med. 1941, 99:551-576.
108. Sabin A.B. Pathogenesis of poliomyelitis: reappraisal in the light of new data. Science 1956, 123:1151-1157.
109. Sabin Measles killer of millions in developing countries: strategy for rapid elimination and continuing control. Eur. J. Epidemiol. 1991, 7:1-22.
110. Sabin A.B., Boulger L.R. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1973, 1:115-118.
111. Salk J.E. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J. Am. Med. Assoc. 1953, 151:1081-1098.
112. Santos C.N., Post P.R., CArvalho R., Ferreira I.I., Rice C.M., Galler R. Complete nucleotide sequence of yellow ever virus vaccine strains 17DD and 17D 213. Virus Res. 1995, 35:35-41.
113. Santos N., Hoshino Y. Global Distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 2005, 15:29-56.
114. Sauder C.J., Vandenburgh K.M., Iskow R.C., Malik T., Carbone K.M., Rubin S.A. Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 2006, 350:48-57.
115. Schlegel M., Vernazza P.L. Immune response and vaccine efficacy. Vaccine 1998, 16:1256.
116. Schmid A., Spielhofer P., Cattaneo R., Baczko K., ter Meulen V., Billeter M.A. Subacute sclerosing panencephalitis is typically characterized by altertions in the fusion protein cytoplasmic domain of the persisting measles virus. Virology 1992, 188:910-915.
117. Schwarz A.I. Preliminary tests of a highly attenuated measles vaccine. Am. J. Dis. Child. 1962, 103:386-389.
118. Shah K., Nathanson N. Human exposure to SV40: review and comment. Am. J. Epidemiol. 1976, 103:1-12.
119. Sharma H.J., Oun S.A., Bakr S.S., Kapre S.V., Jadhav S.S., Dhere R.M., Bhardwai S. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clin. Microbiol. Infect. 2010, 16:347-352.
120. Smorodintsev A.A., Boichuk I.M., Shikina F.S., Batanova T.B., Peradze T.V. Clinical and immunological response to live tissue culture vaccine against measles. Acta Virol. 1960, 4:201-204. (Leningrad 4).
121. Svitkin Y.V., Cammack N., Minor P.D., Almond J.W. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472AU. Virology 1990, 175:103-109.
122. Tatem J.M., Weeks-Levy C., Georgiu A., DiMichele S.J., Gogaez E.J., Racaniello V.R., Cano F.R., Mento S.J. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 Protein is attenuating. J. Virol. 1992, 66:3194-3197.
123. Theiler M., Smith H.H. The use of yellow fever vaccine virus modified by in vitro cultivation for human immunization. J. Exp. Med. 1937, 31:787-800.
124. Ueda S., Takahashi M., Minekawa Y., Ogino T., Susuki N. Studies on further attenuated live measle vaccine. I. Adaptation of measles virus to the chorioallantoic membrane of chick embryo and clinical tests on the strain. Biken J. 1970, 13:111-116.
125. Vesikari T., Isolauri F., D'Hondt E., Delem A., Andre F., Zissis G. Protection of infants against rotavirus diarrhea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984, i 977-981.
126. van Binnendijk R.S., van der Heijden R.W.J., van Amerongen G., UytdeHaag F.C.G.M., Osterhaus A.D.M.E. Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J. Infect. Dis. 1994, 170:443-448.
127. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., Koff W.C. Non human primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 2008, 14:617-621.
128. Westrop G.D., Evans D.M.A., Dunn G., Minor P.D., Magrath D.I., Taffs F., Marsden S., Wareham K.A., Skinner M., Schild G.C., Almond J.W. Genetic basis of attenuation of the Sabin type 3 oral poliovaccine. J. Virol. 1989, 63:1338-1344.
129. Whittembury A., Ramirez G., Hernández H., Ropero A.M., Waterman S., Ticona M., Brinton M., Uchuya J., Gershman M., Toledo W., Staples E., Campos C., Martínez M., Chang G.-J.J., Cabezas C., Lanciotti R., Zaki S., Montgomery J.M., Monath T., Hayes E. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27:5974-5981.
130. WHO, 1966. Requirements for the Production and Quality Control of Smallpox Vaccines (Requirements for Biological Substances No. 5) Revised 1965. In: Technical Report Series 323 Annex 4. WHO, Geneva, Switzerland.
131. WHO Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use with special reference to type 3 poliovirus. Bull. World Health Organ. 1969, 40:925-945.
132. WHO Report Markers of poliovirus strains isolated form cases temporally associated with the use of live poliovirus vaccine: reprt on a WHO collaborative study. J. Biol. Stand. 1981, 9:163-184.
133. WHO, 1983. Requirements for Poliomyelitis Vaccine (Oral) (Revised 1982). Technical Report Series 687, pp. 107-174.
134. WHO, 1988. WHA41.28 Global Eradication of Poliomyelitis by the Year 2000. (last accessed 27.11.14). http://www.who.in.
135. WHO, 2002. Guidelines for the Production and Quality Control of Live Attenuated Japanese Encephalitis Vaccine. Technical Report Series 910 Annex 3.
136. WHO, 2003. Recommendations for the Production and Quality Control of Smallpox Vaccines Revised 2003. In: Technical Report Series 926 Annex 1. WHO, Geneva, Switzerland.
137. WHO, 2005. Guidelines for the production and quality control of candidate tetravalent dengue virus vaccines (live). Technical Report Series 932 Annex 1, pp. 43-72.
138. WHO, 2007. Guidelines to Assure the Quality Safety and Efficacy of Live Attenuated Rotavirus Vaccine (oral). Technical Report Series 941, Annex 3, pp. 133-187.
139. WHO, 2010. Recommendations to Assure the Quality, Safety and Efficacy of Live Attenuated Yellow Fever Vaccines. Technical Report Series 978 Annex 5, pp. 241-314.
140. WHO, 2012. Recommendations to Assure the Quality, Safety and Efficacy of Poliomyelitis Vaccines (oral, live, attenuated) Appendix 2 In Vivo Tests for Neurovirulence and Considerations in Relation to Assay choice. 63rd Report Expert Committee on Biogical Standardization Annex 2; Technical Report Series 980, pp. 108-113.
141. WHO, 2014a. Poliomyelitis. (last accessed 10.12.14). http://www.who.int/polioeradication.org.
142. WHO, 2014b. Questions and Answers on Dengue Vaccines: Phase III study of CYD-TDV. (last accessed 10.12.14). http://www.who.int/immunization/research/development/WHO_dengue_vaccine_QA_July2014.pdf?ua=1.
143. WHO, 2014c. Questions and Answers on Dengue Vaccines: Phase III Study of CYD-TDV. (last accessed 10.12.14). http://www.who.int/immunization/research/development/QA_Dengue_vaccine_LA_phIIIstudy_final.pdf?ua=1.
144. Yamanishi A., Takahashi M., Kuirimura T., Ueda S., Minekawna Y., Ogino T., Suzuki N., Baba K., Okuno Y. Studies on live mumps virus vaccineIII Evaluation of newly developed live mumps vorus vaccine. Biken J. 1970, 13:157-161.
145. Yates P.J., Afzal M.A., Minor P.D. Antigenic and genetic variation of the HN protein of mumps virus strains. J. Gen. Virol. 1996, 77:2491-2497.